VBID Incentives to Improve Medication Adherence and Outcomes among Racial/Ethnic Minority Patients in United States with HIV
Value-Based Insurance Design (VBID) Incentives to Improve Medication Adherence and Outcomes among Racial/Ethnic Minority Patients in United States with HIV: A Feasibility Study
In this project, we propose to extend the value-based insurance design evidence to HIV via a unique collaboration combining the extensive, nationwide reach of Aetna, one of the largest insurers in the United States.
Aim 1: Explore the feasibility of conducting an adherence intervention trial with African American patients.
Aim 2: Examine the distribution of cost sharing and HIV medication adherence by relevant demographic (sex, age, region) and clinical characteristics of the identified patient population in order to estimate sample size requirements and perform power calculations for a full-scale trial of HIV adherence interventions.
Aim 3: Develop processes and procedures for administering VBID-based copayment waivers within Aetna to lay the groundwork for a 12-month randomized clinical trial comparing HIV viral load suppression and medication adherence across three proposed arms: i.) copayment waiver for all HIV medications, administered at point of service ii.) a daily lottery incentive program and iii.) usual care.
Research insights from this study will help health care delivery systems, health insurers, employers, and pharmacy benefit managers develop more effective programs for improving adherence and health within their populations going forward.